Ethical considerations regarding disparities pertaining to kidney transplant patients

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 212-214

  Yost, S E ^a   Srinivas, T ^b   Kaplan, B ^c,d  

^a UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

DRUG COST; ETHNIC DIFFERENCE; GRAFT REJECTION; HEALTH BELIEF; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH INSURANCE; HEREDITY; HUMAN; KIDNEY TRANSPLANTATION; MEDICAL ETHICS; PATIENT ATTITUDE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SOCIAL STATUS; SOCIETY;

BIOMEDICAL RESEARCH; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PATIENT EDUCATION AS TOPIC; REFERRAL AND CONSULTATION; UNITED STATES;

EID: 79960586106     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.73     Document Type: Review

References (5)

1. Schold, J.D. et al. Marked variation of the association of ESRD duration before and after wait listing on kidney transplant outcomes. Am. J. Transplant. 10, 2008-2016 (2010).
2. Kalyer, L.K. et al. Gender imbalance and outcomes in living donor renal transplantation in the United States. Am. J. Transplant. 3, 452-458 (2003).
3. Churack, J.M. Racial and ethnic disparities in renal transplantation. J. Natl. Med. Assoc. 97, 153-160 (2005).
4. MacPhee, I.A.M. et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4, 914-919 (2004). (Pubitemid 38745590)
5. Srinivas, T.R., Kaplan, B., Schold, J.D. & Meier-Kriesche, H.U. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 80, S211-S20 (2005).